Cellestia Biotech AG secures CHF 20 million in Series A funding
Cellestia announced today the close of a CHF 20 million Series A financing round. The financing will accelerate Cellestia’s ongoing clinical program, and advance its innovative R&D pipeline.
To read Cellestia’s press release click here.
Cellestia Winner of Venture Leaders China 2018
Cellestia selected as one of the 10 high growth Swiss start-ups composing the new Swiss National Startup Team. The team will fly to China for an exclusive 10-day roadshow for business and investor meetings in September organised by Venture Leaders / swissnex China, including the World Economic Forum Annual Meeting of New Champions in Tianjin
Cancer Care 2018
Oral presentation on CB-103 by Dr. Dirk Weber, Chief Medical Officer, at the “Cancer Care 2018 Innovation & Progress in Switzerland” meeting (Bern, September 14).